Furthermore, high expression of LAG-3 in TILs has been found to be significantly associated with a poor prognosis for immunotherapy in patients with HCC and, therefore, has the potential to serve as a biomarker to evaluate therapeutic efficacy [18–20]. This evidence concerns the gene LAG3 and hepatocellular carcinoma.